John Weeks1, MD Candidate 2017, Justin Hickman1, MD Candidate 2017

Slides:



Advertisements
Similar presentations
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Advertisements

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Primary care of hypertensive patients and the risk of acute events Irina Stirbu-Wagner Markus MJ Nielen Maaike Langelaan Robert A. Verheij Joke C. Korevaar.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Ambulatory Blood Pressure Profiles in Adolescents with Type 1 Diabetes Andrew J. Ellis 1,2, B.A.; David M. Maahs 2, M.D. Ph.D.; Franziska K. Bishop 2,
Electronic Medical Record Use and the Quality of Care in Physician Offices National Conference on Health Statistics August 17, 2010 Chun-Ju (Janey) Hsiao,
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar Dr.PH. Batch 5 1.
Blood pressure control in primary health care WORKSHOP
Clinical Characteristic of Patients with Uncontrolled, Potentially Under-treated and Apparent Treatment Resistant Hypertension: NHANES 1988  Brent.
Improving Hypertension Quality Measurement Using Electronic Health Records S Persell, AN Kho, JA Thompson, DW Baker Feinberg School of Medicine Northwestern.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients Dr. Mya Thandar.
Utilization Of Lipid-lowering Therapy In Hypertensive Patients In The United States Simon S.K. Tang, MPH* Sean Candrilli, MS** Lizheng Shi, PhD* *Department.
ABSTRACT Diabetes is a public health issue of growing magnitude. It currently ranks among the top ten leading causes of death in the United States. To.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Association between Systolic Blood Pressure and Congestive Heart Failure Complication among Hypertensive and Diabetic Hypertensive Patients Mrs. Sutheera.
Acknowledgements Contact Information Anthony Wong, MTech 1, Senthil K. Nachimuthu, MD 1, Peter J. Haug, MD 1,2 Patterns and Rules  Vital signs medoids.
Association of C-Reactive Protein and Acute Myocardial Infarction in HIV-Infected Patients Virginia A. Triant, MD, MPH, James B. Meigs, MD, MPH, and Steven.
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Connecting Hypertensive Patients at the Physican’s Free Clinic to a Primary Care Provider Ariel Kanevsky, Ranjit Ganguly, Brittany Shrefler, Maarten Galantowicz.
Vitamin D: A New Frontier in Diabetes Management Contact Information: Background Acknowledgement Methods.
Investigation of the Negative Association between Hypertension and Age- Associated Peripheral Neuropathy Dong Yung Cho, MD, James W. Mold, MD, Michelle.
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
Journal Club February 7, 2014 Sadie T. Velásquez, MD.
1 Body-Mass Index and Mortality in Korean Men and Women Sun Ha Jee, Ph.D., Jae Woong Sull, Ph.D., Jung yong Park, Ph.D., Sang-Yi Lee, M.D. From the Department.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Preoperative Anemia and Postoperative Mortality in Neonates Goobie SM, Faraoni D,
©2015 MFMER | slide-1 The Effect of an Automated Point of Care Tool on Diagnosis and Management of Childhood Obesity in Primary Care Natalie Gentile, MD.
Do Short-Term Medical Trips Make a Difference in Treating NCDs? Mark Ryan, MD Goldie Chang, P3; Camille Hochheimer, PhD student; Marwah Khalid, MD; Dien.
Dr John Cox Diabetes in Primary Care Conference Cork
Effectiveness of yoga for hypertension: Systematic review and meta-analysis Marshall Hagins, PT, PhD1, Rebecca States,
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Landon Marshall, Pharm. D. , Matt Hill, Pharm. D. , Jim Wilson, Pharm
Redefining Quality Care in T2DM Patients with CV Disease
Family History Information Helps Inform Chronic Pain Treatment
Single IMA {Single Arterial}
C Wilson, KM Rhodes, RA Payne
Cheryl Schraeder, RN, PhD, FAAN Health Systems Research Center
Hypertension November 2016
Diabetes and Hypertension Health Screening in the Fresno Sikh Population: A Cross Sectional Approach Baljit Singh Dhesi 1,2 1University of California,
The Role of Depression in Effective Chronic Disease Management
Patient Registries and Health Outcomes in Diabetes: A Retrospective Study Nipa Shah, MD1; Fern Webb, PhD1; Liane Hannah, BSH1; Carmen Smotherman, MS2;
Daily Stress, Coping, and Nocturnal Blood Pressure Dipping
Itamar Grotto, Michael Huerta, Ehud Grossman and Yehonatan Sharabi
Exercise Adherence in Patients with Diabetes: Evaluating the role of psychosocial factors in managing diabetes Natalie N. Young,1, 2 Jennifer P. Friedberg,1,
Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.
Health and Human Services National Heart, Lung, and Blood Institute
American Public Health Association Annual Meeting
Non-Communicable Diseases Risk Factors Survey in Georgia
How can we measure success? Clinical Outcome Measures for a
Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from the Irish Longitudinal Study on Ageing.
Jan B. Pietzsch1, Benjamin P. Geisler1, Murray D. Esler 2
Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study M. Lazo, Y. Chen, J.W. McEvoy, C. Ndumele, S. Konety,
Health during transition to adulthood in the population with learning disabilities: analysis of Scotland’s Census (2011) Ms Genevieve Young-Southward1,
Alina M. Allen MD, Patrick S. Kamath MD, Joseph J. Larson,
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Differences by HIV Serostatus in Coronary Artery Disease.
Chapter 1: CKD in the General Population
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
University of Witwatersrand, Johannesburg, South Africa
ASPIRE Workshop 5: Application of Biostatistics
ASPIRE Workshop 5: Application of Biostatistics
Teaching Tool: Blood Pressure Classification
Systolic Blood Pressure Intervention Trial (SPRINT)
Chapter 1: CKD in the General Population
Hypertension November 2016
Abstract Decreased Inappropriate Antibiotic Use Following a Korean National Policy to Prohibit Medication Dispensing by Physicians Sylvia Park, PhD; Stephen.
ASPIRE Workshop 5: Application of Biostatistics
Chronic Disease Under Control: Managed Care Plan Distribution, 2006
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
ANZDATA: Vascular Access
Presentation transcript:

John Weeks1, MD Candidate 2017, Justin Hickman1, MD Candidate 2017 Impact of Implementing an Electronic Medical Record on an International Medical Mission John Weeks1, MD Candidate 2017, Justin Hickman1, MD Candidate 2017 Camille Hochheimer2, PhD Candidate, Mark Ryan1, MD Virginia Commonwealth University School of Medicine, Richmond, Virginia Virginia Commonwealth University, Department of Biostatistics, Richmond, Virginia Background The sample analyzed consisted of adult patients who visited the clinic in 2015 (pre-EMR), as well as those who visited in 2016 (post-EMR implementation). Data utilized included age, gender, systolic and diastolic BP, CVD risk, and up to ten medications. Established non-laboratory CVD risk calculation charts were utilized to determine a CVD risk of Low, Moderate or High3. Patients with High CVD risk have a 5 year risk of fatal & non-fatal events of >20%3. Patients were considered treated for high CVD risk if prescribed a statin and treated for HTN if prescribed an anti-hypertensive. Patients with systolic BP >140mmHg and/or a diastolic BP >90mmHg were designated as BP above goal. Univariate logistic regression determined whether gender and/or age was significantly associated with each outcome and if so were included as a covariate in the final logistic regression. 3. Gaziano, T., Young C., Fitzmaurice G., Atwood S., Gaziano J. (2008) Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 371, 923–31. Materials & Methods 30% 71% 77% 87% Figure 1. Percentage of patients receiving treatment with a statin for high CVD risk. Figure 2. Percentage of patients receiving treatment for HTN Results The sample consisted of 349 patients from 2015 (pre-EMR group) and 262 patients from 2016 (post- EMR group). Gender and age were not significantly associated with any outcome except BP above goal and, thus, were only entered into that model. 71% of patients with high CVD risk in the post-EMR group received a statin compared to only 30% in the pre-EMR group (p<0.001). Significantly more patients with BP >140/90 were receiving HTN treatment post-EMR vs pre-EMR (87% and 77% respectively, p=0.044). Although 71% of patients with high CVD risk post- EMR were prescribed aspirin vs. 57% pre-EMR, this difference was not significant (p=0.066). Discussion Limitations / Future Directions With the implementation of fEMR on our STMT, it was found that significantly more high CVD risk patients and patients with a BP >140/90 post-EMR implementation were receiving treatment. This suggests that fEMR better facilitates the identification of high risk patients and their appropriate treatment. Although more patients with a high CVD risk post-EMR were receiving aspirin, it was not significant likely due to the high prevalence of low dose aspirin use in the DR. A longitudinal analysis might be a more appropriate way to analyze BP trends after implementation of the EMR. A limitation of this study is that some patients could be repeat patients returning for another visit, in which case the samples from 2015 and 2016 are not truly independent. Future analyses could include matching on age and gender, although these factors do not appear to play a major role except in the case of elevated BP. fEMR has proven to be a powerful tool in data collection and analysis for STMTs. Next steps should include: Further utilizing accumulated digitized data to question and research community health issues and foster new research questions. Continued technological development of features, prompts and automation of fEMR to enhance functionality and quality of care. Short Term Medical Trips (STMT) are often vital in bringing healthcare to underserved/under-resourced communities who may rely largely on such medical missions for their primary health care needs. According to the WHO in all regions of the world outside of Sub-Saharan Africa, chronic disease is the number one cause of mortality1. In the Dominican Republic (DR), 15% of patients were diagnosed with diabetes and 73% with hypertension (HTN)1. 95% of short term medical mission trips demonstrated no meaningful collection of data2. Lack of accumulated medical data reduces quality of long term care and makes evaluation of the effects of medical missions difficult to establish. This study examined the use of “fEMR” (http://teamfemr.org), a simple portable Electronic Medical Record (EMR), and the effects of its implementation on a STMT to the DR related to the treatment of cardiovascular disease (CVD) risk factors. Research Question Does the implementation of a portable EMR impact quality of care and management outcomes on an STMT quantified through medical management of CVD & HTN? Is the proportion of patients with a high CVD risk who are receiving a statin different before vs. after EMR implementation? Is the proportion of patients with a high CVD risk who are receiving aspirin different before vs. after EMR implementation? Is the proportion of patients with a blood pressure (BP) above goal different before vs. after EMR implementation? Is the proportion of patients with BP above goal who are being treated for HTN different before vs. after EMR implementation? 1. Acosta, D., Rottbeck, R, Rodriguez, J, Gonzalez, L, Almanazar, M, Minaya S., Del C. Ortiz, M, Ferri, C, and Prince, M. (2010). The prevalence and social patterning of chronic diseases among older people in a population undergoing health transition. A 10/66 Group cross-sectional population-based survey in the Dominican Republic. BMC Public Health. 10, 344-349. 2. Sykes, K.J. (2014) Short-Term Medical Service Trips: A Systematic Review of the Evidence. American Journal of Public Health: Vol. 104, No. 7, e38-e48. Non-HypertensiveNon-Hypertensive 369 (58) Hypertensive 265 (42) Characteristic Pre-EMR (2015) Post-EMR (2016) Age 52.7 (12.6) 53.6 (13.5) Gender (% female) 73.2% (254) 73.5% (191) High CVD risk 33.0% (105) 33.0% (75) Receiving aspirin 34.1%( 119) 37.0% (97) Receiving a statin 16.1% (56) 32.4% (85) HTN treatment 49.9% (174) 60.3% (158) Systolic BP 138.3 (25.1) 136.6 (24.9) Diastolic BP 85.0 (14.9) 83.6 (13.7) Table 1. Characteristics of the Pre and Post EMR Groups - mean(std) or percentage(n) 89 (33) Outcome OR 95% CI p-value Receiving a statin 5.75 3.00 11.02 <0.001 Receiving aspirin 1.81 0.96 3.39 0.066 BP above goal 0.72 0.51 1.02 0.068 HTN treatment 2.09 4.29 0.044 Acknowledgments DEPARTMENT OF BIOSTATISTICS Table 2. Odds ratios comparing post-EMR to pre-EMR patients